BioInsights - Preparing next-gen cellular immunotherapies for commercialization

Preparing next-gen cellular immunotherapies for commercialization

Cell & Gene Therapy Insights 2022; 8(5), 587–593

DOI: 10.18609/cgti.2022.090

Published: 16 May 2022
Interview
Peter Olagunju

David McCall, Editor, Cell & Gene Therapy Insights, talks to Peter Olagunju, Chief Technology Officer, TCR² Therapeutics

Peter Olagunju is a Cell & Gene Therapy Executive, who has successfully worked to drive four C> products through clinical development to commercialization: PROVENGE®, ZYNTEGLO®, ABECMA®, and SKYSONA®. Mr Olagunju joined TCR² in 2021 as Chief Technology Officer. He brings over 20 years of experience in cell and gene therapy, clinical development, program management, manufacturing and technical operations. Prior to joining the company, he was Senior Vice President of Technical Operations at FerGene Inc., where he led the technical operations function for the commercialization of a gene therapy for bladder cancer. Before that, Mr Olagunju was Vice President of Global Patient Operations at bluebird bio, Inc., where he held several roles of increasing responsibility and was the program lead and functional head of manufacturing supporting the European approval for ZYNTEGLO®, a transformational gene therapy for Transfusion dependent Thalassemia. Earlier in his career, he held senior positions in Commercial Technical Operations and served as the Head of Quality at Dendreon Corp. and ZymoGenetics, Inc. Mr Olagunju holds an MBA from the University of Washington and a BS in Biology from the University of Illinois at Urbana–Champaign.